CAR-T therapy is one of the most striking advances in modern medicine: a treatment made from a patient’s own immune cells, re-engineered to hunt down disease. It has produced lasting remissions in blood cancers that had resisted everything else, and researchers are now testing whether it can reset the immune system in autoimmune diseases such as lupus and multiple sclerosis. Here is how it works, in plain language.

What CAR-T stands for

T cells are white blood cells that kill infected or abnormal cells. A chimeric antigen receptor (CAR) is an artificial sensor that scientists add to a T cell’s surface. It combines the targeting part of an antibody, which recognizes a specific marker on a target cell, with the signaling machinery that tells the T cell to attack. A CAR-T cell is therefore a T cell that has been given a new target and a strong instruction to kill it.

How the treatment is made

The process usually takes several weeks:

  • Collection. Blood is drawn and T cells are filtered out in a procedure called leukapheresis.
  • Engineering. In a specialized facility, a harmless virus delivers the gene for the CAR into the T cells, which are then multiplied into hundreds of millions.
  • Preparation. The patient receives a few days of chemotherapy to make room for the new cells.
  • Infusion. The CAR-T cells are given back through a drip, usually once.
  • Monitoring. Patients are watched closely for several weeks for side effects.

Once infused, the cells multiply in the body and can persist for months or years — which is why CAR-T is often called a “living drug.”

What it treats today

All approved CAR-T therapies are for blood cancers. Those targeting CD19, a marker on B cells, treat certain lymphomas and B-cell acute lymphoblastic leukemia; they include Kymriah, Yescarta, Tecartus, Breyanzi and Aucatzyl. Those targeting BCMA, found on plasma cells, treat multiple myeloma: Abecma and Carvykti. In some of these cancers, a single infusion has produced remissions lasting years in patients who had run out of options, and CAR-T is steadily moving earlier in the course of treatment.

The side effects

Two reactions are characteristic. Cytokine release syndrome (CRS) happens when activated T cells flood the body with inflammatory signals, causing fever, low blood pressure and breathing difficulty; it ranges from mild to life-threatening and is treated with drugs such as tocilizumab and steroids. Neurotoxicity (ICANS) can cause confusion, difficulty speaking, tremor or, rarely, seizures, and is usually temporary. Because CD19 therapies also destroy healthy B cells, patients can have low antibody levels and infections for months. The FDA has also added a warning about a small risk of secondary T-cell cancers. As centers have gained experience, the agency has eased some monitoring and travel-restriction requirements.

Why solid tumors are harder

CAR-T has worked far better in blood cancers than in solid tumors such as lung, breast or colon cancer. Solid tumors rarely have a marker that is on every cancer cell and absent from vital healthy tissue; they are physically hard for T cells to penetrate; and they create a local environment that switches immune cells off. Newer designs with multiple targets or built-in boosters are in trials, with early signs of progress in some cancers, but this remains the field’s biggest unsolved challenge.

The new frontier: autoimmune disease

In autoimmune diseases, B cells make antibodies that attack the body. Around 2021, German doctors began treating people with severe lupus using CD19 CAR-T. The results were remarkable: deep elimination of B cells was followed by drug-free remission that persisted even after new, healthy B cells returned — as if the immune system had been rebooted. Trials have since expanded to systemic sclerosis, inflammatory muscle disease, myasthenia gravis and multiple sclerosis.

Results reported in 2026 from company-run trials have been encouraging, with substantial improvements in disease activity and patients able to stop their other medicines, and with CRS and neurotoxicity generally milder than in cancer. But follow-up is still short, some patients have relapsed, and safety is not settled: at least one company has reportedly paused an autoimmune CAR-T program after patient deaths. No CAR-T is yet approved for an autoimmune disease.

Cost and access

CAR-T is expensive, with list prices of roughly $400,000 to $500,000 for the product alone, before hospital care. It is offered only at certified centers, and manufacturing takes weeks that some very sick patients do not have. Insurers and Medicare cover approved uses, but distance from a treatment center and time off for patients and caregivers remain real barriers.

What comes next

Three developments could make CAR-T simpler. “Off-the-shelf” (allogeneic) products use cells from healthy donors, made in advance. In vivo CAR-T skips the lab entirely, delivering instructions by injection so T cells are engineered inside the body; early human studies, including in autoimmune disease, have shown that this is possible. And T-cell engagers, proteins that link T cells to their targets, offer a related, less complex approach — a field seeing major investment, as in Novartis’s recent deal.

For patients, the practical message is that CAR-T is an established option for certain blood cancers and an experimental one for autoimmune disease, available through clinical trials. Whether it is appropriate depends on the diagnosis, previous treatments and overall health, and is a decision for a specialist team. This explainer is general information, not medical advice.